Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 1, 2007, Pages 211-217

  Salmon, Beth A ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

CA4P; KHT sarcoma; Tumor perfusion; Vascular targeting

Indexed keywords

OXYGENATION; PATHOLOGY; PHOSPHATES; PHYSIOLOGY; RADIOTHERAPY; TUMORS;

ANTICANCER THERAPIES; COMBRETASTATIN A4 PHOSPHATE (CA4P); TUMOR RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ONCOLOGY;

COMBRETASTATIN A4 PHOSPHATE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TREATMENT RESPONSE; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EXPERIMENTAL; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 34247173906     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.12.051     Document Type: Article

References (31)

1. Folkman J. How is blood-vessel growth regulated in normal and neoplastic tissue-Gha Clowes Memorial Award Lecture. Cancer Res 46 (1986) 467-473
2. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood-vessels during tumor angiogenesis. Microvasc Res 14 (1977) 53-65
3. Denekamp J. Endothelial cell-proliferation as a novel approach to targeting tumor therapy. Br J Cancer 45 (1982) 136-139
4. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
5. Hashizume H., Baluk P., Morikawa S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156 (2000) 1363-1380
6. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., and McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160 (2002) 985-1000
7. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163 (2003) 1801-1815
8. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9 (1990) 267-282
9. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
10. Kanthou C., and Tozer G.M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99 (2002) 2060-2069
11. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 (2004) 415-427
12. Tozer G.M., Kanthou C., Parkins C.S., and Hill S.A. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83 (2002) 21-38
13. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17 (2005) 277-290
14. Siemann D.W. Vascular targeting agents: an introduction. Int J Radiat Oncol Biol Phys 54 (2002) 1472
15. Chaplin D.J., and Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br J Cancer 80 Suppl. 1 (1999) 57-64
16. Siemann D.W. Vascular targeting agents. Horizons Cancer Ther 3 (2002) 4-15
17. Rojiani A.M., Li L., Rise L., and Siemann D.W. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol 41 (2002) 98-105
18. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57 (1997) 1829-1834
19. Lash C.J., Li A.E., Rutland M., Baguley B.C., Zwi L.J., and Wilson W.R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78 (1998) 439-445
20. Horsman M.R., and Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57 (2003) 1047-1055
21. Kallman R.F., Silini G., and Van Putten L.M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst 39 (1967) 539-549
22. Siemann D.W., and Rojiani A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62 (2005) 846-853
23. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
24. Bilenker J.H., Flaherty K.T., Rosen M., et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11 (2005) 1527-1533
25. Horsman M.R., Chaplin D.J., and Overgaard J. The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother Oncol 20 Suppl. 1 (1991) 47-52
26. Tannock I., and Hill R. The basic science of oncology (1998), McGraw-Hill, 3rd ed. New York
27. Sheng Y., Hua J., Pinney K.G., et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 111 (2004) 604-610
28. Bouis D., Kusumanto Y., Meijer C., Mulder N.H., and Hospers G.A. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 53 (2006) 89-103
29. Siemann D.W., and Rojiani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54 (2002) 1512-1517
30. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53 (2002) 164-171
31. Siemann D.W., Mercer E., Lepler S., and Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99 (2002) 1-6